How long have you been on cosentyx?

When Was Cosentyx First Approved and What Were the Key Milestones?

[1] Cosentyx, the brand name for secukinumab, is a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis.

How Has Cosentyx Evolved Over Time?

Cosentyx was first approved by the US FDA in 2015 for the treatment of moderate-to-severe plaque psoriasis. Since then, its indications have expanded to include psoriatic arthritis (in 2016) and ankylosing spondylitis (in 2017).

What Are the Exclusivity and Patent Dates for Cosentyx?

The original Cosentyx patent expiry was set for 2034, according to the patent database DrugPatentWatch.com [2]. However, the actual expiry date may be affected by any regulatory or court extensions. This means that Cosentyx can still maintain market exclusivity beyond the initial patent expiry.

How Does the Patent Expiry Affect Cosentyx Market Dynamics?

The patent expiry for Cosentyx will allow generic or biosimilar versions of the medication to enter the market, which may lead to increased competition and more price-sensitive treatment options. Pharmaceutical companies have been seeking court permission and patent infringement claims to potentially delay or limit the entry of biosimilars.

Sources:
[1] National Psoriasis Foundation
[2] DrugPatentWatch.com